• Comment: Nothing has changed since the previous denial. QuicoleJR (talk) 19:22, 6 January 2025 (UTC)

• Comment: Since this went through a deletion discussion 3 months ago you have to do considerable better, particularly since his publication record is very weak.
  1. Remove all the fluff about "Letter of commendation", " Citation" and similar, these are routine, WP:MILL.
  2. Notability is not inheritable, as previously stated. Please remove who he collaborated with as irrelevant.
  3. Pages he wrote are not independent. In any case most of those in sources 1-7, 22-27 do not show notability. Neither 28 nor 29 contribute anything useful.
  4. All his career needs sourcing.
  Read carefully WP:NPROF. As discussed in the AfD, there is no proof that he passes any of the criteria, you have to demonstrate this, WP:BURDEN. Ldm1954 (talk) 14:36, 2 January 2025 (UTC)

• Comment: A honorary professorship doesn't indicate notability. Also note that Wikipedia doesn't know the principle of inherited notability, i.e., it doesn't matter who confirmed the subjects scientific discoveries or whom the subject collaborated with. Please make sure that the text is based on reliable secondary sources; the text is almost exclusively based on what the subject says about himself, and "Congress, The Library of". Maybe, you should cite more "Congress, the Library of", I reckon he is a knowledgeable person. (In case this isn't obvious: I'm joking. Please fix your citations if you deem the subject sufficiently notable for inclusion in Wikipedia!) --Johannes (Talk) (Contribs) (Articles) 18:45, 28 October 2024 (UTC)

Roberto G. Carbone (Roberto Giovanni Carbone) (born in Genoa, Italy - 6 September 1954) is an Italian scientist, clinician and professor studying the mechanisms and treatment of pulmonary fibrosis such as extracellular matrix, global idiopathic pulmonary fibrosis genome, discoverer of pulmonary hypertension as the most important cause of mortality in cardiopulmonary diseases, lung cancer mechanisms as confirmed by Prof. Robert P. Baughman, University of Cincinnati with whom he studied the pathophysiology, diagnosis and therapy of sarcoidosis.^[1]

Furthermore he collaborated with D. Geraint James regarding the treatment of sarcoidosis. He is an expert in lung transplantation, asbestosis and mesothelioma.^[2] He also studied the role of neuropeptides (neurotensin) in asthma adrenergic and recently his research focused on stem cells post acute myocardial infarction(AMI).^[3] in collaboration with Harvard University.

Carbone was born in Genoa. His father, Giuseppe Carbone, was deputy managing executive director of the Gilardini Company. Carbone graduated from the University of Genoa in Medicine and Surgery in 1983. In 2003, he was registered with the General Medical Council and is collaborating closely with the Chair of General Medical Council Dame Carrie MacEwen.^[4] He obtained a master's degree in pulmonary hypertension from the University of Michigan, and further master's degrees in respiratory medicine and bronchology from the National Heart and Lung Institute directed by Peter J. Barnes at Imperial College London, in asthma and phenotypes at the University of Denver directed by Sally Wenzel, in pneumology at University of Montpellier, and in asthma and COPD from the University of Ferrara. After specializing in pulmonary diseases and respiratory pathophysiology, he‘s appointed assistant and deputy head physician in Department Internal Medicine at Regional Aosta Hospital. From 2017 Carbone is part of the TopMed program (NIH, USA) in the study of genetics and the genome and telomeres.^[5] From 2020 to 2022, he worked as a clinical researcher at University of Genoa.^[6] In 2023, he became a Fellow of the Royal Society of Medicine, London. Carbone was awarded an honorary professorship in 2022 and is a senior consultant cardio-respiratory physician at the Department of Internal Medicine in the University of Genoa.^[7] In November 4th 2024 He was appointed Professor Medicine in University of Genoa.

His research initially focused on the study of alpha-1 antitrypsin deficiency pulmonary emphysema, and urinary degradation products (desmosine) and prolastin treatment working in the lab of Gordon L. Snider for the project The American-Italian AATD Study Group^[8](Harvard University). He has collaborated in the field of lung disease therapy with Prof. Silvio Garattini of the Mario Negri.

He dedicated himself to the study of physiology of lung cancer in collaboration with Renato Dulbecco Physiology or Medicine) subsequently creating the first Italian Cancer Registry with the patronage of the Istituto Superiore di Sanità in the figure of Marco Geddes di Filicaja, at IST (Scientific Institute of Tumors) in Genoa under the direction of Leonardo Santi. He studied the pathologies of asbestos, such as pleural mesothelioma at Scansetti Interdepartmental Center in Turin where he collaborated with Roberto Compagnoni of University of Turin and Bice Fubini also enrolled in the Academy of Sciences of Turin. Subsequently, he studied the role of neuropeptides (neurotensin) in asthma adrenergic regulation with Giovanni Bottino^[9] (University of Genoa). He went on to win the first prize as researcher with Professor Giovanni Bottino in the Italian CHEST Congress (American College of Chest Physicians). The study entitled In vivo the micro-environmental reactivity in asthmatic took place over a period of 15 years and since our understanding was the first study in the world to evaluate bronchial hyper-reactivity in asthmatic subjects in vivo and in vitro^{[10] [11]}

In 1999 Carbone was the first in the world that is discovered through the study of Indium the higher accuracy with respect to tracer Gallium 67 in the study of Interstitial Lung Disease with and without pulmonary hypertension associated with a high mortality rate and the pilot study was presented personally in USA on October 2001 at World CHEST Meeting.^[12] His first book and unique book in the world where the association with Pulmonary Arterial Hypertension and Interstitial Lung Diseases was discussed and published in 2009. The book is widespread in every part of the world, and notably is held in Capitol Hill Library (Washington D.C.), at MIT in Boston, at the National Institute of Health, at Moscow University and is also in widespread readership in China.This book is a seminal text which introduced conjoined treatment of pulmonary hypertension and pulmonary fibrosis following a report of Carbone at International Congress "World Association Sarcoidosis and Other Granulomatous Disorders' ' (WASOG) in Denver in 2005 ^[13] (Washington D.C.)^[14] at MIT in Boston, at the National Institute of Health, at Moscow University and is also in widespread readership in China.^[15] This book is a seminal text which introduced conjoined treatment of pulmonary hypertension and pulmonary fibrosis since the International Congress "World Association Sarcoidosis and Other Granulomatous Disorders"(WASOG) in Denver in 2005.^[16] His third book entitled Lung Transplantation - Evolving Knowledge and New Horizons, a collaboration with Mario Viganò contains a first chapter entitled "The History of Lung Transplantation"^[17] which is considered by the Book Authority one of the best books on thoracic surgery of all time. In 2023 this is positioned fifty-second in the "Best Thoracic Surgery eBooks of all time" ranking.^[18] In 2007, William (Bill) D. Travis, directed Carbone to the study of pneumonia of the pulmonary interstitium in the lung deep area which was not attributable to inflammation bacteria or viruses, rather of unknown cause. In 2016 Carbone always a passionate scholar of cardiopulmonary physiology and circulation, as ACCP Leadership at the CHEST Meeting in Los Angeles, interviewed Dr Karlman Wassermann, creator of the cardiopulmonary stress test. ^[19] Carbone discovered through the study of Indium and pulmonary hypertension that fibrotic pneumonia has a high mortality rate.^[20] Since 2017, he has been a Member of Global IPF Collaborative Network, a Platform for IPF Genetics for University of Genoa, Principal Investigator Prof. David Schwartz MD from University of Colorado Anschutz Medical Campus.^[21] The scope of the study is to further understand the genetics of IPF by collecting more than 10,000 ethnically diverse cases of Idiopathic Pulmonary Fibrosis (IPF) with the collaboration of 70 international investigators (40 sites).^[22]

Carbone^[23] is the author^[24] of over 150 publications^[25] in peer-reviewed journals.^[26] He was a member of the editorial board of the scientific journal CHEST and is an associate editor of the journal Frontiers^[27] and Editorial Board of THE LANCET. He has published 5 books^[28] in English as a Scientific Editor.^[29] as a scientific editor. Scopus reported over 1140 citations.^[30]

• 1994: First prize, as speaker and author, 8th World Congress of Bronchology in Munich. Title of the study:"The open window thoracoscopy procedure for bronchopleural fistula with persistent empyema following pneumonectomy".
• 1997: Fellow of the American College of CHEST Physicians (ACCP)^[31]

• 1998: Roberto Giovanni Carbone Delegation Italy CHEST (American College of Chest Physicians)

• 2000: First prize, as speaker and author together with Professor Giovanni Bottino at National Congress of CHEST (American College of Chest Physicians). Title of the study: "In vivo microenvironmental reactivity in asthma"
• 2003: Letter of Commendation from Editor-in-Chief of CHEST Journal (IF 10), Prof. A Jay Block MD, Master FCCP, Professor Emeritus of Medicine, University of Florida.
• 2004 - 2019: Served in a number of leadership roles at the American College of Chest Physicians^[32]
• 2006: Member of American delegation National Institute of Health (NIH) in association with "People to People Ambassador Program" (Head of Delegation Prof. Denis Mc Cool, Brown University), with the support of Prof. Claude Lenfant (Director of National Heart, Lung, and Blood Institute) for scientific exchanges between United States and CHINA – President People to People (USA) Dr. Mary Jean Eisenhower.
• 2009: Letter of Commendation from Editor-in-Chief of Annals of Internal Medicine (IF 39.2), Professor Harold C Sox, MD, MACP, USA.
• 2009: Letter of Commendation from Professor Robert P. Baughman (Director of Respiratory Medicine, University of Cincinnati for published book project, title: "Pulmonary Arterial Hypertension and Interstitial Lung Diseases. A Clinical Guide".
• 2009: Invitation from Editor-in-Chief of Thorax (IF 9.02) to join the journal's editorial board
• 2010: Citation from Editor-in-Chief of British Medical Journal (IF 105.7) for the article on the topic of risk factors in Cardiology
• 2012: American Thoracic Society Leadership for COPD (National Quality Form USA).
• 2012: Steering Committee Member of Network Cardiovascular Medicine and Surgery, with Alberto Ballestrero and Vincenzo Savarino (Dept. Internal Medicine, University of Genoa).^[33]
• 2015 - 2019: Governor for Italy regarding American College of Chest Physicians

• 2017: Personal invitation letter from the President of the American Thoracic Society to participate in the World Meeting which took place in May 2017 in Washington (DC) as an International Member representing Italy
• 2017: Invitation of the Swiss Confederation of Pneumology to CHEST Meeting in Basel
• 2018: Member and Leadership for the University of Genoa of OSIC (Open Source Imaging Consortium). Principal Investigator: Professor Simon Walsh, National Heart and Lung Institute, Imperial College, London, Radiology Leader
• 2023: Fellow of the Royal Society Medicine in London.

• 2023: Fellow of the American Heart Association.^[34]
• 2024: Received King Charles III Honor and Proud Letter from Professor Roger Kirby, President Royal Society Medicine and confirmed by the current President Gillian Leng.

• 2024: Appointed by Richard Horton, Editorial Board of THE LANCET, Impact Factor 98.4.
• 2024: Appointed to the National Academy of Sciences Sigma Xi .^[35]
• 2024: Appointed Professor Medicine University of Genoa.
• 2024: Member of The American Heart Association Council in Cardiopulmonary, Critical Care, Perioperative and Resuscitation (3CPR)^[36]
• 2024: Appointed Associate Editor for the Journal Frontiers in Medicine^[37]